Citigroup Cuts IQVIA (NYSE:IQV) Price Target to $210.00

IQVIA (NYSE:IQV) had its price objective reduced by Citigroup from $225.00 to $210.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

Several other research firms have also recently weighed in on IQV. UBS Group lowered their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Robert W. Baird dropped their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Morgan Stanley boosted their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Price Performance

IQV stock opened at $185.45 on Tuesday. The firm has a 50 day moving average of $197.95 and a 200-day moving average of $213.47. The firm has a market capitalization of $32.70 billion, a P/E ratio of 24.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA has a 12 month low of $179.28 and a 12 month high of $261.73. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts predict that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Institutional investors have recently added to or reduced their stakes in the company. Siemens Fonds Invest GmbH raised its stake in shares of IQVIA by 973.2% during the fourth quarter. Siemens Fonds Invest GmbH now owns 21,345 shares of the medical research company’s stock valued at $4,195,000 after acquiring an additional 19,356 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in IQVIA during the 4th quarter valued at about $25,152,000. Forum Financial Management LP raised its position in IQVIA by 53.2% during the 4th quarter. Forum Financial Management LP now owns 2,067 shares of the medical research company’s stock valued at $406,000 after purchasing an additional 718 shares during the last quarter. Toronto Dominion Bank lifted its holdings in IQVIA by 2.2% in the 4th quarter. Toronto Dominion Bank now owns 61,774 shares of the medical research company’s stock worth $12,139,000 after buying an additional 1,358 shares during the period. Finally, GF Fund Management CO. LTD. bought a new stake in shares of IQVIA in the 4th quarter worth approximately $841,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.